Results 91 to 100 of about 76,259 (245)
Expert Perspective: Diagnosis and Treatment of Castleman Disease
Summary Castleman disease (CD) is a major diagnostic challenge for Rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y.C. Chen+2 more
wiley +1 more source
Aims The study aims to predict and improve the absorption of tyrosine kinase inhibitors (TKIs) in patients with malabsorption issues, particularly those who have undergone bariatric surgery or are using proton‐pump inhibitors. The research involves 2 main components: the development of an artificial intelligence (AI) model to identify TKIs that are ...
Daan W. Huntjens+8 more
wiley +1 more source
Engineering antibodies with cancer‐associated binding sites
This review describes antibodies that perform direct/indirect roles in cancer treatment by binding to effective targets and discusses how antibodies kill tumors and modulate tumor microenvironment through these targets. The classification of expression systems for antibody production is summarized to guide appropriate selection based on different ...
Yinqi Tian+4 more
wiley +1 more source
Effect of urethane on a Transplantable Acute Lymphoid Leukemia.
SummaryUrethane, administered intraperitoneally in subanesthetic dose, 0.75 mg per g of body weight per day in leukemic mice transplanted with leukemic cells of the 32nd to 34th transfer generations of an acute lymphoid leukemia, produces the following profound palliative effects: (1) The blood leukocytes are maintained at leukopenic levels.
openaire +3 more sources
Abstract Epigenetic regulation plays an important role in cell fate reprogramming. Here, we found that inhibitors of epigenetic modifiers, including VPA, TSA, and 5‐Aza‐2'‐deoxycytidine, can induce phenotypic transformation from Jurkat cells into B‐cell‐like cells. When Jurkat cells were treated with 5‐Aza combined with VPA, B cell and stem cell marker
Wenjin Xi+11 more
wiley +1 more source
Blinatumomab in the Therapy of Acute B-Lymphoid Leukemia.
Blinatumomab, a CD19-CD3 bispecific T cell engager (BiTE), has two recombinant single-chain variable fragments that temporarily link CD3+ T cells and CD19+ B cells, leading to the T cell-mediated lysis of neoplastic B cells. Improved minimal residual disease (MRD)-negative response rates and long-term overall survival have been observed in B-ALL ...
Testa U.+3 more
openaire +4 more sources
Abstract Background Overweight and obesity are known risk factors for cancer. The aim of this study was to investigate associations of body mass index (BMI) and waist circumference (WC) with incidence of 27 site‐specific cancers stratified by sex and menopausal status accounting for non‐linearity.
Seonghye Kim+7 more
wiley +1 more source
ABSTRACT The subfamily Gomphrenoideae is composed of about 480 accepted species, many of which have been historically used as medicinal plants, reason why they have been studied in terms of chemical profile, biological activity, and safety. This review consolidates the advances in research on this subfamily over the past 47 years, emphasizing its ...
Dayanna Isabel Araque Gelves+3 more
wiley +1 more source
Skeletal lesions in acute lymphoid leukemia.
[No abstract available]
M. Pigna+4 more
openaire +2 more sources